The Ministry of Health is considering various strategies to mitigate the transmission of HIV linked to injectable drug use, with the safe syringe program being a significant option. Health Minister Dr. Atonio Lalabalavu emphasized in Parliament that while exploring these solutions is crucial, it is equally important not to imply that the ministry supports drug use.
Dr. Lalabalavu stated that this issue needs to be assessed within the context of Fiji’s circumstances. He noted that the safe syringe initiative should be framed not only as a means to prevent transmission from injectable drug use but also to avoid promoting increased drug usage.
The minister highlighted that, despite a global decline in HIV cases, Fiji’s situation is concerning, marking the country as the second fastest-growing in new HIV infections in the Asia-Pacific region, following the Philippines. He revealed to Parliament that 15 percent of the 552 new HIV cases reported in the first half of 2024 were associated with injectable drug use.
Efforts are ongoing to enhance access to HIV testing and treatment services nationwide, promote harm reduction initiatives, and combat stigma and discrimination against those affected by HIV. The Fiji National HIV Surge Strategy for 2024-2027 is being finalized and will be presented to the Cabinet. This strategy outlines five priority areas aimed at reducing HIV transmissions while ensuring public health treatment, care, human rights, and social justice for individuals with HIV.
For the fiscal year 2024/2025, the government has allocated $200,000 for HIV/AIDS prevention and control programs, with plans to seek additional funding from donors and relevant stakeholders. Dr. Lalabalavu mentioned the initiative to decentralize point-of-care testing to subdivision hospitals and health centers. He remarked that the recent rise in HIV cases is largely attributed to an increase in testing efforts.